MOR/0.2R

96042335, human lung, Not specified

• 分類程式碼代碼: 41106514
• 生物源: human lung
• 增長模式: Semi-adherent aggregates
• 染色體組型: Not specified
• 形態學: Not specified
• 產品: Not specified
• 受體: Not specified
• 相關疾病: cancer

屬性

• 產品名稱: MOR/0.2R, 96042335
• 生物源: human lung
• 增長模式: Semi-adherent aggregates
• 染色體組型: Not specified
• 形態學: Not specified
• 產品: Not specified
• 受體: Not specified
• 技術: cell culture | mammalian: suitable
• 相關疾病: cancer
• 運輸包裝: dry ice
• 儲存溫度: −196°C

描述

細胞系來源

Human lung adenocarcinoma, drug-resistant

細胞系描述

The drug resistant cell line MOR/0.2R has been derived from the parent line, MOR, by continuous exposure to increasing concentrations of doxorubicin (also known as adriamycin). MOR/0.2R accumulate lower levels of doxorubicin than the parent line and have been shown to overexpress multi drug resistance associated protein (MRP). Expression of a 190kDa membrane protein associated with the degree of drug-resistance has been indicated. Cells grow as easily detaching aggregates.

應用

Analysis of acquired drug resistance, MRP studies

培養基

RPMI 1640 + 2mM Glutamine + 0.2μg/ml Doxorubicin + 10% Foetal Bovine Serum (FBS).

例行更新培養

Split subconfluent cultures (70-80%) 1:2 to 1:4 seeding at 2-4 x 10,000 cells/cm² using 0.25% trypsin or trypsin/EDTA; 5% CO₂; 37°C. It is recommended to culture the cells without drug after resuscitation until the first passage. These cells produce a

其他說明

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.